FIELD: chemistry.
SUBSTANCE: invention relates to a method of producing crystalline form I 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide, characterized by characteristic peaks at the following positions on the XRPD diagram, expressed in values of angle 2θ: 9.498 ± 0.2°, 12.293 ± 0.2°, 13.045 ± 0.2°, 15.899 ± 0.2°, 16.199 ± 0.2°, 18.183 ± 0.2°, 18.327 ± 0.2°, 21.755 ± 0.2°, 22.362 ± 0.2°, 25.690 ± 0.2°, or characteristic peaks at 8.968± 0.2°, 9.498 ± 0.2°, 12.293 ± 0.2°, 13.045 ± 0.2°, 15.899 ± 0.2°, 16.199 ± 0.2°, 16.533 ± 0.2°, 16.908 ± 0.2°, 18.183 ± 0.2°, 18.327 ± 0.2°, 20.042 ± 0.2°, 20.271 ± 0.2°, 21.755 ± 0.2°, 22.362 ± 0.2°, 25.690 ± 0.2°. Method involves crystallisation 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide in an organic solvent, wherein the crystallisation method is stirring at room temperature or adding an anti-solvent; crystallization temperature is 20–50 °C. If crystallisation is carried out by means of a stirring method at room temperature, the organic solvent is heptane, methanol, ethanol, isopropanol, methyl-tert-butyl ether, acetonitrile, acetone, 2-butanone, ethyl acetate and isopropyl acetate; if an anti-solvent is used for crystallisation, the organic solvent is DMSO; anti-solvent is water, isopropanol and acetonitrile.
EFFECT: obtaining crystalline form I 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide, having good stability, with high reproducibility.
5 cl, 59 dwg, 24 tbl, 30 ex
Title | Year | Author | Number |
---|---|---|---|
AZABICYCLIC COMPOUND CRYSTALS | 2016 |
|
RU2697521C2 |
CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
CRYSTALS OF 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND | 2016 |
|
RU2672563C1 |
COMPOUNDS AND METHODS FOR INHIBITING JAK | 2016 |
|
RU2760359C2 |
POLYMORPHIC MODIFICATIONS OF N-[(3-FLUORO-4-METHOXYPYRIDINE-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({ 4-[(2-OXOPYRIDINE-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AND THEIR SALTS | 2017 |
|
RU2756273C2 |
SALT OF MU-OPIOID RECEPTOR (MOR) AGONIST, CRYSTAL FORM I OF ITS FUMARATE SALT, AND THEIR PRODUCTION METHOD | 2018 |
|
RU2779119C2 |
6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND ITS APPLICATION IN MEDICINE | 2018 |
|
RU2792694C2 |
MULTIKINASE INHIBITOR COMPOUND AND ITS CRYSTALLINE FORM AND USE | 2017 |
|
RU2723985C1 |
CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
PRODRUGS OF PYRIDONAMIDES USED AS MODULATORS OF SODIUM CHANNELS | 2014 |
|
RU2692766C1 |
Authors
Dates
2024-11-01—Published
2021-07-01—Filed